Seres Therapeutics ^Partner

Seres Therapeutics is a late-clinical-stage biotechnology company dedicated to developing microbiome-based therapeutics for serious diseases linked to microbial imbalances. Founded in 2011 and publicly traded on NASDAQ under the ticker MCRB, the company utilizes its Ecobiotic® platform to create live bacterial consortia aimed at restoring healthy microbiome function.

The company focuses on treating conditions such as recurrent infections and immune-mediated gastrointestinal disorders by addressing dysbiosis, which is the imbalance of microbial communities. Its pipeline includes SER-109, a Phase 3 oral therapeutic for preventing recurrent *Clostridium difficile* infection, and SER-262, a Phase 1b synthetic microbiome therapeutic. Seres also offers VOWSTâ„¢, the first FDA-approved oral live biotherapeutic for CDI prevention.

Seres Therapeutics primarily serves medically vulnerable populations, aiming to reduce reliance on antibiotics and meet the needs of patients with infectious and immune-related diseases. The company is committed to advancing microbiome therapeutics as a key component of modern medicine.